ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) CFO John T. Cavan acquired 20,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was acquired at an average price of $0.65 per share, for a total transaction of $13,000.00. Following the purchase, the chief financial officer now directly owns 20,000 shares of the company’s stock, valued at $13,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) traded down 0.5511% during trading on Thursday, hitting $0.6316. The stock had a trading volume of 223,152 shares. ContraVir Pharmaceuticals Inc has a 52 week low of $0.60 and a 52 week high of $2.65. The company’s 50 day moving average price is $0.67 and its 200 day moving average price is $1.29. The company’s market capitalization is $40.24 million.

COPYRIGHT VIOLATION WARNING: “Insider Buying: ContraVir Pharmaceuticals Inc (CTRV) CFO Acquires 20,000 Shares of Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/06/22/insider-buying-contravir-pharmaceuticals-inc-ctrv-cfo-acquires-20000-shares-of-stock.html.

Several research firms have issued reports on CTRV. Noble Financial restated a “buy” rating on shares of ContraVir Pharmaceuticals in a research note on Friday, April 21st. Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, April 11th.

Institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC increased its position in shares of ContraVir Pharmaceuticals by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares of the biopharmaceutical company’s stock valued at $1,820,000 after buying an additional 8,862 shares during the period. Morgan Stanley increased its position in shares of ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares of the biopharmaceutical company’s stock valued at $493,000 after buying an additional 1,119 shares during the period. Geode Capital Management LLC increased its position in shares of ContraVir Pharmaceuticals by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares of the biopharmaceutical company’s stock valued at $626,000 after buying an additional 7,057 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares of the biopharmaceutical company’s stock valued at $3,626,000 after buying an additional 189,634 shares during the period. 6.45% of the stock is owned by hedge funds and other institutional investors.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.